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Abstract: Senescence is the end point of a complex cellular response that proceeds through a set of 
highly regulated steps. Initially, the permanent cell-cycle arrest that characterizes senescence is a 
pro-survival response to irreparable DNA damage. The maintenance of this prolonged condition 
requires the adaptation of the cells to an unfavorable, demanding and stressful microenvironment. 
This adaptation is orchestrated through a deep epigenetic resetting. A first wave of epigenetic 
changes builds a dam on irreparable DNA damage and sustains the pro-survival response and the 
cell-cycle arrest. Later on, a second wave of epigenetic modifications allows the genomic 
reorganization to sustain the transcription of pro-inflammatory genes. The balanced epigenetic 
dynamism of senescent cells influences physiological processes, such as differentiation, 
embryogenesis and aging, while its alteration leads to cancer, neurodegeneration and premature 
aging. Here we provide an overview of the most relevant histone modifications, which characterize 
senescence, aging and the activation of a prolonged DNA damage response. 
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1. Introduction 
Aging is a physiological condition characterized by the functional deficit of tissues and organs 
due to the accumulation of senescent cells [1]. The key role of senescence in aging is well-established. 
Clearance of senescent cells in mouse models delays the appearance of age-related tissue and organ 
disfunctions [2,3]. Senescent cells are characterized by the permanent cell-cycle arrest sustained by 
the accumulation of cyclin-dependent kinase inhibitors/CDKi), like p16, p21 and p27, as well as by 
the release of cytokines, chemokines and soluble factors. This modified microenvironment is known 
as senescence-associated secretory phenotype (SASP) [4]. The senescence state is triggered by 
different stimuli/stressors. These include the shortening of the telomeres (replicative senescence), the 
oncogene-induced replication stress, the oncogene-induced senescence (OIS), the accumulation of 
misfolded protein and/or oxidative stress (stress-induced premature senescence, SIPS) [5]. 
The impairment of the non-homologous end joining (NHEJ) and homologous recombination 
(HR) repair mechanisms are common traits of senescent cells [6–9]. Moreover, a widespread 
epigenetic resetting characterizes senescent cells and sustains cell-cycle arrest and cellular survival, 
through the activation of (i) CDKi [10,11], (ii) tumor suppressors [12], and (iii) secretion of 
chemokines and cytokines, as well as the remodeling of the microenvironment [13]. 
Macroscopically, senescent cells are characterized by the formation of peculiar areas of 
heterochromatin, named as SAHF (senescence-associated heterochromatin foci), mainly at E2F loci 
[14]. However, SAHF do not characterize all senescent cells [15] and are not causally linked to the 
onset of senescence [16]. Other epigenetic features, like the distension of satellites (senescence-
associated distension of satellites, SADS) [17], the re-activation of transposable elements, and of 
endogenous retroviruses (ERV) [18,19], seem to better qualify different types of senescence. Finally, 
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aging appears to be marked by substantial re-arrangements of the nucleosomes, with the loss of 
histones H3 and H4 [20,21]. 
During senescence the epigenome undergoes temporal and sequential modifications that are 
mandatory to accomplish different cellular adaptations. Initially, this epigenetic resetting is mainly 
due to the accumulation of irreparable DNA damage. After this first wave of epigenetic 
modifications, the epigenome is remodeled and fixed in order to sustain the permanent cell-cycle 
arrest and to modulate the microenvironment. 
2. The Epigenome of Replicative Senescence (RS) 
The telomeric TTAGGG repeats at chromosome ends protect the genome from degradation and 
distinguish natural chromosomes ends from double-strand breaks (DSBs) [5,22,23]. Histone and non-
histone (Shelterin) proteins sustain the folding of telomeric repeats in high-order chromatin 
structures that acquire a G-quadruplex shape as a consequence of Hoogsteen base pairing between 
consecutive guanines [24]. The loss of active telomerase complexes in somatic human cells blocks the 
lengthening of the telomeric ends. As a consequence, for each successful cell division, telomeres get 
shorter and cell proliferation is restricted. This phenomenon is defined as replicative senescence (RS) 
[25]. The accumulation of irreparable DNA damage triggered during RS leads to permanent cell-cycle 
arrest and is considered among the main driving forces of aging [22]. 
2.1. Histone Variants 
The progressive accumulation of double-strand breaks (DSBs) at the chromosome ends is 
coupled with a deep epigenetic resetting that can be observed in pre-senescent cells, even distal from 
telomeres. This epigenetic repertoire builds up an epigenetic clock that dictates the replicative 
potential of human cells [26]. Late passage IMR90 and WI38 human fibroblasts are characterized by 
a reduced expression of core histone H3 and H4 [21], of the linker histone H1 [27] and of the histone 
chaperons ASF1A/B and CAF1-p150/p60 [28]. While the decreased levels of H3 and H4 are due to 
reduced neosynthesis and increased mRNA degradation [21,29], H1 is post-translationally regulated 
[27]. Moreover, alternative spliced histone mRNAs belonging to the HIST1 cluster are reported to be 
accumulated in quiescent and RS-arrested human fibroblasts [30]. 
The epigenome of RS cells is also characterized by the deposition, at certain genomic loci, of the 
histone variants H3.3 [31], H2A.J [32] and by the release of genomic DNA from H2A.Z [33–35] (Table 
1). This redistribution results in chromatin remodeling and promotes the transcription of (i) tumor 
suppressors [30,31], (ii) inflammatory genes marking the SASP, [32] and iii) the cleavage of H3.3, 
which mediates the repression of E2F/RB target genes [31]. While in senescence, the HIRA-mediated 
deposition of H3.3 sustains cell-cycle arrest [31], and in embryonic stem cells ATRX and DAXX recruit 
H3.3 to repress the transcription of endogenous retroviruses (ERVs) [36]. 
It is possible that the redistribution of H3.3 between the proliferating and senescent cells, which 
depends on the detachment from ATRX/DAXX and the complexing to HIRA, is at the basis of the 
activation of ERVs observed in senescence [37] and aging [38]. 
The regulated deposition of all these histone variants is necessary [30] and sufficient to sustain 
cell-cycle arrest [31]. Interestingly, genes encoding these histone variants are frequently mutated in 
cancer, in confirmation of their tumor-suppressive properties [30,39]. 
2.2. SAHF an Open Question? 
The HIRA chaperone complex (HIRA/UBN1/CABIN1) controls both the deposition of H3.3 [30] 
and SAHF formation [40]. SAHF accumulation of H3K9me3/H3K27me3/macroH2A blocks on E2F 
loci characterizes OIS and cells undergoing oncogene-induced replication stress [15]. However, RS is 
not uniformly characterized by the formation of SAHF [41]. In fact, focused heterochromatinization 
of E2F loci maintains cell-cycle arrest, also in cells described as SAHF-negative (e.g., BJ and MEFs) 
[41,42]. SAHF are defined as DAPI-dense nuclear regions characterized by the presence of a central 
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core of condensed chromatin, enriched for H3K9me3 and macroH2A. This core is surrounded by a 
peripheral ring of H3K27me3 [43,44]. SAHF formation requires p16/INK4 and consists of a deep and 
focused heterochromatin re-organization [45]. This reorganization is HMGA1/ASF1/HIRA-
dependent [40,46] and is triggered by the GSK3β-mediated HIRA re-localization at PML bodies [47]. 
Even though SAHF dismantling, achieved through HMGA1 [46], ASF1 [40] or GSK3β knockdown 
[48], allows senescence escape, BJ fibroblasts and Hutchinson–Gilford progeria syndrome (HGPS) 
cells enter senescence with minimal or no signs of SAHF formation. On the opposite, the SAHF 
formation in HMEC and MCF10A mammary cells in response to H-RAS/G12V over-expression fails 
to bring the cells to senescence [15]. Whether SAHF formation is only due to the arising of replication 
stress and could act as a barrier to DNA double-strand breaks spreading [15], or could mark 
chromatin regions stitched between remodeled LAD domains [45], needs further investigation. It is 
possible that a better definition of the SAHF, achieved through the improvement of the resolution of 
confocal nanoscopy and of ChIP-seq histone mapping, will clarify the debated role played by SAHF 
in senescence. 
2.3. Histone Modifications 
A global decrease in H3K9me2/3 and H4K20me but increase in H3K9me1 levels in gene bodies 
characterize RS in human fibroblasts [49,50]. By contrast, the heterochromatin marker H3K27me3 and 
the euchromatin marker H3K4me3 are mostly redistributed with respect to proliferating cells (Table 
2). 
This redistribution correlates well with the expression profile of senescent cells [51–53]. A 
different behavior was reported for the repressive mark H4K20me3 and the activating mark 
H4K16ac. Although they are enriched in the regulative elements of genes modulated during RS, they 
do not correlate with gene expression changes observed in senescent cells [30,54]. This apparent 
paradox could stem from the masking effect imposed by the senescence-specific activation of super-
enhancers (marked by H3K27ac/H3K4me1) and the activation of neighbor genes involved in SASP 
and metabolism [55]. 
A detailed comparison of H3K4me3 and H3K27me3 levels in proliferating and senescent human 
fibroblasts evidenced large-scale chromatin modifications during RS [56]. In senescent cells the 
augmented levels of H3K4me3 and H3K27me3 frequently co-localize in areas defined “mesas” that 
extend for hundreds of kilobases. Larger domains of RS genome (up to 10Mb) and defined “canyons” 
are characterized by decreased levels of H3K27me3 [56]. H3K4me3 and H3K27me3 mesas colocalize 
in LMNB1-associated domains and overlap DNA hypomethylation. Instead, canyons are enriched in 
gene bodies and enhancers and H3K27me3 loss correlates with the up-regulation of senescent 
transcriptional programs [56]. 
2.4. Nuclear Lamins 
The loss of LMNB1 typifies all senescence conditions [57] and triggers a deep re-modelling of 
lamina-associated domains (LADs) [44,56]. LADs re-modelling contributes to re-organizing not only 
heterochromatin and SAHF [44], but also euchromatin (eLADs) [58]. Moreover, the knockdown of 
LMNB1 in proliferating cells promotes the premature senescence and gives rise to a 
H3K4me3/H3K27me3 re-organization similarly to what observed in RS, OIS and HGPS [56]. 
However, LMNB1 re-expression in RIS senescent cells does not overcome the proliferation of arrest 
and does not repair nuclear membrane blebbing [59]. It is still unknown if the re-expression of 
LMNB1 in senescent cells is strong enough to re-establish normal LAD domains or if the co-
expression of an epigenetic regulator is needed. Similarly, the ectopic expression of lamina-associated 
polypeptide 2α restores the proliferation of HGPS cells [60], characterized by the expression of the 
progerin form of LMNA [61,62]. Unfortunately, the impact of LAP2α expression on LAD domains 
has not been explored yet. The re-localized LAD domains in RS are characterized also by a general 
DNA hypomethylation that affects LINE and SINE repetitive elements and pericentromeric satellites 
[17]. This hypomethylation triggers the general distension of the chromatin associated to these 
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genomic regions (senescence-associated distension of satellites or SADS) and their de-repression [17]. 
The activation of centromeric and pericentromeric satellite repeats is associated with their exclusion 
from nucleoli compartments, while all the other nucleoli-associated domains (NADs) are significantly 
altered in senescent cells [63]. 
Despite LADs redistribution, 3D chromatin organization of human dermal fibroblasts (HDFs) is 
only partially altered when proliferating, quiescent and senescent cells are compared. A modest gain 
of short-range and the loss of long-range intra-chromosome interactions in permanently arrested cells 
was observed [64]. More evident in quiescent and senescent cells is the switch of topologically 
associated domains (TADs) from euchromatin areas (Hi-C compartment A) to heterochromatin (Hi-
C compartment B) and vice versa. This remodeling reflects the transcriptional status of cell-cycle-
associated genes [64]. Most of the heterochromatinization is due to condensin mobilization [65] and 
PRC2 (EZH2) deposition [66], while MLL1 plays a role in mediating euchromatinization [67,68]. 
Moreover, RS cells lose the TADs associated to the telomeres [69]. 
2.5. The CpG Methylation Clock 
In general, DNA methylation during aging progressively involve both hypomethylation and 
hypermethylation events. Importantly, the methylation status of a limited number of well-defined 
CpG islands associate well with human aging [26]. The quantification of the methylation rate of these 
CpG island allows a good prediction of human biological age [26,70–72]. According to these 
estimations, the methylome of men ages 4% faster than women [70]. Moreover, the methylation clock 
is accelerated in patients affected by neurodegenerative diseases [73–75], chronic stress and insomnia 
[76], as well as in two premature aging disorders like Werner’s syndromes and Hutchinson–Gilford 
Progeria syndrome [76,77], while it is subverted in cancer [78,79]. 
Aging is characterized by enhancer hypomethylation [41] and this correlates with the loss-of-
function of stem cells [80]. Similar changes in the methylation prolife also characterize RS [81], and 
global hypomethylation characterizes both genomic and mitochondrial DNA [82]. CpG 
hypermethylated regions are associated with H3K27me3, H3K4me3 and H3K4me1, whereas 
hypomethylation is observed in the constitutive heterochromatin and lamina-associated domains 
(LADs) [83]. 
3. The Epigenome of Oncogene-Induced Senescence (OIS) 
The expression of a certain number of oncogenes (K-RAS and H-RAS, BRAFV600E, myrAKT1, 
STAT5, nuclear HDAC4, N1ICD, ERBB2 and β-catenin) [84–92] or ablation of tumor suppressors 
(PTEN, APC and AXIN) in normal cells triggers a permanent and premature cell-cycle arrest defined 
as OIS [93,94]. OIS can occur also in the presence of ectopic TERT expression [6]. The most studied 
model of OIS is the RAS-induced senescence (RIS), obtained by over-expressing oncogenic mutants 
of RAS in fibroblasts, melanocytes and retinal pigment epithelial cells. The consistency of the RIS 
model has been validated in mice, after conditional induction of the monoallelic expression of K-
RAS/G12V. Mice develop lung adenomas characterized by the accumulation of senescent cells [95]. 
Similarly, premature senescence blocks the spreading of oncogenic lesions in BRAF/V600E 
expressing melanocytic nevi [89]. Curiously, RAS fails to induce senescence in immortalized human 
mammary epithelial cells (HMECs), even after the ectopically expression of p16/INKa [96,97]. This 
failure has been associated to defects in the TGFβ signaling pathway [97]. 
It is generally accepted that the premature cell-cycle arrest characterizing OIS is elicited by the 
accumulation of irreparable DNA damage. In fact, the abrogation of ATM signaling allows 
senescence escape [6]. It is important to note that the DDR dependence was observed for RAS but its 
involvement in the case of other oncogenes, such as NOTCH and AKT1, needs further validations 
[90,98]. As explained above, RIS is characterized by the accumulation of SAHF [14]. However, the 
oncogenic activation of AKT1 and NOTCH or the knockdown of PTEN trigger OIS without SAHF 
formation [85,86,98]. In the case of NOTCH, this is due to the repression of HMGA1 [90]. Differently, 
in the case of AKT1 it was hypothesized a mechanism operating through GSK3β inhibition. In fact 
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GSK3β controls the phosphorylation-dependent HIRA sub-compartmentalization [99]. In this 
respect, a similar defect in HIRA signaling prevents SAHF formation in senescent murine embryonic 
and skin fibroblasts expressing RAS, but not to the accumulation of nuclear macroH2A.1 [42]. The 
deposition of the histone variant macroH2A.1 is not only required for SAHF formation. It also 
sustains a chromatin re-organization that allows the focused histone acetylation and the expression 
of the typical SASP cytokines and chemokines [100]. Moreover, the knock-down of macroH2A.1 in 
H-RAS/V12 IMR90-expressing cells not only blunts SASP, but also decreases the phosphorylation of 
γH2AX [100]. 
A common property of OIS cells is the loss of LMNB1 [57]. This causes a deep re-organization 
of LAD domains [44], similarly to what was observed during RS [56]. As a consequence, OIS is 
characterized by the re-localization and re-organization of LAD-associated heterochromatin domains 
[43,101]. This re-organization is sculptured in the distribution of H3K4me3 and H3K27me3 “mesas” 
and H3K27me3 “canyons”, as described above for RS cells [56]. Interestingly, the expansion of 
H3K27me3 “canyons” achieved though EZH2 repression sustains OIS by promoting the expression 
of cytokines [56] and of CDKi [66,102,103]. 
Similarly to RS, the histone variant H3.3 [31,104] and its Cathepsin L-mediated cleavage product 
H3.3cs1 [104] are deposited in RIS cells in the regulative elements of RB/E2F target allowing the 
permanent removal of H3K4me3 [31] and the increase in H3K9me3 levels [14]. Contemporary, the 
removal of H2A.Z and the de-methylation of H3K27me3 at tumor suppressor loci sustains cell-cycle 
arrest [33,66]. The inflammatory response is achieved through the deposition of the histone variant 
H2A.J [32] and the binding of HMGB2, which excludes these loci from SAHF [41]. HMGB2 also allows 
the H3K4 trimethylation mediated by the methyltransferase MLL1 [53]. Moreover, SASP loci are 
localized in newly formed super-enhancers that require the binding of BRD4 to promote their 
transcription [105,106]. 
Finally, OIS in human fibroblasts is characterized by the spatial rearrangement of pre-existing 
heterochromatin that give rise to SAHF [45]. Differently, HGPS cells are refractory to SAHF formation 
[45,107,108] and to heterochromatin focusing [45], probably because the huge alterations in the 
lamina compartment of these cells prevents the proper heterochromatin 3D-structure organization 
[109]. A similar displacement of H3K9me3 from LADs is observed in OIS, but it is followed by an 
increase in local interactions between H3K9me3 domains and sharp heterochromatinization [45]. 
Curiously and differently from RS and aging, OIS cells do not display any changes in CpG island 
methylation levels [110]. 
Different Types of OIS? 
While studies are increasingly describing RIS epigenetics, detailed data about the epigenetic 
modifications in other types of OIS are unavailable. Additional data are desirable since increasing 
evidences highlight the key roles played by epigenetic regulators in maintaining OIS and 
counteracting oncogenic transformation [84,111–116]. For example, in melanomas the activation of 
H3K9me3 demethylases (LSD1 and JMJD2C) selectively de-represses E2F target genes, allowing 
senescence escape and tumorigenesis [117]. This result reinforces the idea that a better investigation 
of the epigenetic mechanism that sustains the early step of tumorigenesis is desperately needed. 
4. The Epigenome of Stress Induced Premature Senescence (SIPS) 
SIPS is characterized by the accumulation of ROS (reactive oxygen species), due to mitochondrial 
disfunctions, ER stress or the exogenous administration of oxidative compounds [118–120]. Even 
though SIPS onset is independent from telomere attrition, ROS accumulation can cause telomere 
disfunction and fusion in primary cells, thus sustaining cell-cycle arrest [120,121]. Accordingly, 
murine embryonic fibroblasts (MEFs) cultured in normoxia undergo premature senescence due to 
the accumulation of ROS-induced DNA damage, while the same cells cultured in hypoxia tend to 
indefinitely proliferate in virtue of the long telomeres [122]. 
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When human cells are exposed to oxidative stress in vitro, they undergo stochastic 
transcriptional changes which resemble aged tissue. Recently, it has been demonstrated that 
oxidative stress contributes not only to aging but also to age-related diseases [123]. Moreover, the 
accumulation of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) has been observed in the liver of 
aged mice [124]. Global histone methylations of H3K4, K27 and K9 are increased when BEAS-2B cells 
are exposed to H2O2, and preincubation with ascorbate reverse these changes [125]. These evidences 
are confirmed also in other contexts [126]. The general heterochromatinization observed after H2O2 
treatment is achieved in two steps. Firstly, by reducing acetylation (H3K9ac, H4K8ac, H4K16ac) 
[125,127] in a HDAC-dependent manner [127,128]. Secondly, by recruiting histone 
methyltransferases (HMTs) and inducing H3K27me3, H3K9me3 and H4K20me3 [127,129]. 
Chromatin condensation is an attempt to preserve the DNA from genotoxicity [130]. 
The downstream pathways that lead to cell-cycle arrest in cells exposed to oxidative stress imply 
the up-regulation of CDKi, the DDR response and SASP production, similarly to cells undergoing RS 
[131,132]. In addition, mitochondrial dysfunctions in IMR90 human fibroblasts lead to the ROS–JNK 
retrograde signaling pathways, which promote SASP and drive cytoplasmic chromatin fragments 
(CCFs) [133]. Importantly, the epigenetic homeostasis perturbation, achieved through HMTs or 
HDACs inhibition [129], is reported to expose cells to endogenous ROS production [134] or to trigger 
and sustain the senescence induced by the treatment with oxidative compounds [135]. In particular, 
some ROS generators inhibit PRC2 methyltransferases to allow the focused demethylation and 
transcriptional activation of CDKi [132]. Similarly, the senescence entry of PAK2 knocked-down 
MEFs cultured in normoxia is delayed because of the decreased deposition of H3.3 on CDKi loci [136]. 
At the DNA level, SIPS is characterized by a global DNA hypomethylation that only partially 
overlaps with the one observed during RS [81]. 
The altered expression and activation of epigenetic regulators allows cancer cells to escape cell-
cycle arrest and to proliferate even in the presence of high levels of oxidative and replication stress, 
perpetuating the accumulation of DNA damage from generation to generation [137]. In short, histone 
variants and histone posttranslational modifications taking place during senescence are listed in 
Tables 1 and 2. 
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Table 1. Histone variants that characterize senescence. RS: Replicative senescence; OIS: Oncogene 
induced senescence; SIPS: Stress induced premature senescence; SASP: Senescence associated 













H1 Chromatin condensation   NI [27] 
H2A Chromatin condensation 
Increased ratio 
H2A2/H2A1 
NI NI [15,40] 
H3, H4 Chromatin condensation    [21] 
H2A.X Sensor of DNA damage    [21] 
H2A.J Promote SASP    [32] 
H2A.Z Regulation of CDKi   NI [33,34] 
H3.3, H3.3cs1 
Gene activation, silencing, 
chromosome segregation 
   [31,36,104] 
H3.1 
Gene activation, silencing, 
chromosome segregation 
 NI NI [21] 
Table 2. Histone post-translation modifications (PMTs) observed in senescence. RS: Replicative 
senescence; OIS: oncogene induced senescence; SIPS: Stress induced premature senescence; SASP: 
Senescence associated secretory phenotype; ↑: Increased expression; ↓: Decreased expression; →: No 
change; NI: Not investigated. 
Histone 
PMTs 




























of Suv420h2  
Heterochromatin gene 
repression  










DNA repair, chromatin 
compaction 
   [125,127] 
H3K9ac HAT/p300 Euchromatin,    [55,125,127] 
H4K8ac HAT/p300 Euchromatin NI NI  [125,127] 
5. The Epigenome at DSBs and during DDR: Early Epigenetic Events in the Senescent Response 
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Double-strand DNA breaks cause massive epigenetic changes. Immediately, at the damaged 
sites, the DNA unwraps from the histones and the chromatin undergoes a de-structuration, thus 
losing compactness [138]. This response is achieved mainly through the chaperone-mediated 
nucleosomes disassembly [139]. Functionally, it allows the recruitment of proteins involved in DDR. 
Structurally it causes significant topological alterations in the DNA fiber. These modifications are 
limited by the subsequent heterochromatinization upstream and downstream from the damage site, 
which restrains relaxation [140]. 
The phosphorylation by PIKK kinases (ATM, ATR and DNA-PK) of ser 139 of H2AX (γH2AX) 
is the widespread histone modification that extends for megabases around a DSBs. γH2AX acts as a 
platform for the recruitment of MDC1 and 53BP1. This recruitment is sustained by the accumulation 
at the damaged site of DDR RNAs [141]. The general relaxation of the chromatin is achieved through 
different mechanisms, which include i) the RNF8/Ubc13/HUWE1 ubiquitylation of Histone H1 
[142,143], ii) the RNF168 mediated K63-ubiquitylation of H2A/B and H2AX [144], and iii) the 
PARylation-dependent, proteasomal degradation of H1.2 [145]. 
In addition to these huge chromatin remodeling, local histone modifications surrounding the 
DSBs take place in cells undergoing NHEJ or HR, thus sculpturing an epigenetic pattern specific for 
each of the two repair mechanisms [138]. The activation of NHEJ is supported by a general chromatin 
expansion around the DSBs, by the deposition of the histone variants H3.3 [146] and H2AZ [147] and 
by the monoubiquitylation of H2BK120. This monoubiquitylation promotes the appearance of 
H3K4me3 and the binding of the SWI/SNF remodeling complex. Moreover, the TIE2-mediated 
phosphorylation of H4Y51 [148], as well as the RNF20/40-mediated H2BK120ub [149] and the 
RNF168-mediated H2AK15ub [144] act as platforms to recruit DDR proteins, like ABL1 [148], 
Ku70/80 [149] and 53BP1 [150,151]. The latter modification and the successful recruitment of 53BP1, 
which controls end re-sectioning, dictate the choice of the NHEJ pathway in spite of HR [152,153]. 
H4K20me2 is another anti-resection modification that reinforce 53BP1 binding to the chromatin [154]. 
However, the co-presence of H2AK15Ub and H4K20me2 in the proximity of the DSBs buffers NHEJ 
processing by recruiting the HAT Tip60/KAT5, which triggers H2AK15ac and 53BP1 displacement. 
An activity that favors the establishing of HR [155]. 53BP1 displacement seems to occur during S/G2 
transition, as in G1 cells 53BP1 stably occupying the HR sites [156]. The general loss of nucleosome 
occupancy achieved in proximity to DSBs is counterbalanced by the distal accumulation of 
H3K36me3 [156]. This PTM can be used as a scaffold for the binding of HDACs, thus ensuring the 
transcriptional silencing of genomic loci affected by DSBs [157,158]. 
A different epigenetic environment is associated to the activation of the HR pathway [158]. In 
this context, macroH2A is found to be more abundant than H2AZ, the acetylation of H2BK120 
overcomes ubiquitylation in a SAGA complex-dependent manner [159] and γH2AX is more spread 
[156]. As explained above, Tip60/KAT5 acetylates H2AK15, thus displacing 53BP1 [155]. Tip60/KAT5 
also maintains the acetylation of H4K16, which is required for keeping an open chromatin status [160] 
at the damaged site. An opposite epigenetic mark, H3K9me2, is required for the BARD1/HP1γ 
mediated retention of BRCA1 [161] and to allow the loading of the pro-resection factor CtIP [162]. In 
active genes affected by DSBs, the loss in H3K79me2 and of H4 acetylation levels [156], as well as the 
recruitment of macroH2A [163] and of repressive protein complexes 
(HP1,KAP1,SUV39H1,PRDM2,HDACs), seems to compensate for the general loss of histones that 
characterizes the damaged sites [164]. The spatio-temporal regulation of chromatin remodeling at 
DSBs is achieved and sustained also by the deposition of other histone variants, like the HIRA-
assisted H3.3 and the CAF-1-mediated H3.3 [23]. 
In summary, from the literature emerges a bleeding/vasoconstriction model in which the 
chromatin expands and becomes flexible at the damaged sites to accommodate the repair complexes, 
but heterochromatinization and the creation of a transcriptional repressive environment is required 
later on to allow the repair before restarting the transcription. The successful prediction of DSBs by 
looking at the histone positioning and PTMs [165], the emerging roles played by epigenetic regulators 
in DDR as well as the impact of epigenetic drugs on DDR [166] confirm that the epigenetic status of 
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the chromatin not only identifies sites of genome fragility, but it is also causally linked to the 
successful repair [23]. 
6. An Anti-Apoptotic Response Sustains the Survival of Damaged Cells Exposed to Irreparable 
DNA Damage 
Senescent cells display an increased resistance to pro-apoptotic stimuli that is achieved through 
the up-regulation of the pro-survival gene Bcl2 and Bcl-XL and the down-regulation of the pro-
apoptotic genes Bid and Bax [127]. The TP53-dependent up-regulation of the CDKi p21 plays a key 
role in sustaining the survival of damaged cells [167], while DNMT3a and HDAC1 are recruited on 
the p21 promoter to switch off its expression during apoptosis [168]. The increase in p21 promotes 
the cell-cycle arrest allowing the activation of DDR; cellular proliferation is subsequently 
permanently locked through the activation of INK4 CDKi (mainly p16 and p15) [169]. Many of the 
anti-apoptotic functions of p21 are achieved through the modulation of TFs (p300, STAT, JUN and 
TP53) [170] and are sustained by an epigenetic reprogramming [127]. In senescent cells, high levels 
of H4K20me3 and low levels of H4K16ac keep down the transcription of pro-apoptotic genes, while 
the increased acetylation of H4K16 characterizes pro-survival loci [127]. The heterochromatinization 
that surrounds and borders DSBs enhances these pro-survival responses and any relaxation of these 
structures, obtained for example through HDAC inhibition, triggers apoptosis [6]. Finally, the 
mTORC1 and PGC-1β dependent metabolic reprogramming [171] observed in senescent cells and in 
different models of aging [5] ensures energy supply. 
Since the epigenetic regulators require cofactors that are produced in a large majority in 
mitochondria [172,173], any mitochondrial dysfunction can affect both the transcriptional and the 
metabolic fitness of the cells and lead to senescence even in absence of DNA damage (MiDAS, 
mitochondrial dysfunction-associated senescence) [171]. 
Severe and acute stresses induce cell death, while prolonged and mild insults lead to cellular 
senescence and survival, probably because the cells have the time and a not completely compromised 
ability to mount the epigenetic, transcriptional and metabolic responses that characterize them [174]. 
7. Final Considerations: The Link between Senescence, Aging, Epigenetics and DDR 
The accumulation of DSBs is a general hallmark of senescence and aging [6]. The main 
endogenous sources of DSBs are telomere attrition and replicative stress. Replication stress is 
commonly observed in RS, OIS and aging. In all these conditions cells slow down DNA synthesis and 
replication fork progression. However, the reduced replication fork speed activates dormant origin 
to preserve replication timing during replication stress [175]. This adaptive response allows the 
maintenance of an unaltered replication timing also in cells entering senescence [176]. On the other 
side it exposes common fragile sites (CFSs), which are genomic loci more prone to breakage after 
DNA polymerase inhibition, and the accumulation of genomic alterations. CFS alterations are 
typically observed in pre-neoplastic lesions [177]. Similarly, cells exposed to genotoxic agents (e.g., 
chemotherapeutic agents, pollutants and toxins) or to oxidative stress activate the DDR that 
frequently leads to cell-cycle arrest. 
Whatever the origin, the accumulation of irreparable DNA damage gives rise to a univocal 
response characterized by the activation of tumor suppressors and CDKi and by the release of pro-
inflammatory cytokines [5]. 
Global histone loss, as well as the focused deposition of histone variants (H2AX, H2AZ, H2AJ, 
H3.3 and macroH2A) and the redistribution of H3K4me3, H3K27me3 and H3K36me3 characterize 
both DDR, DSBs and senescence. The chromatin remodeling observed in different senescence models 
seems to represent a temporal and spatial evolution of what is observed after a short-time treatment 
of the cells with DNA damaging agents. Although it is clear that an altered epigenome can expose 
cells to DSBs [134] and that epigenetic regulators control the fate of damaged cells [15,55,66,115,178–
180], investigations on the epigenetic inheritance in daughter cells coming from DNA-damaged cells 
are still in their infancy [177]. 
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Cancer cells appear as forgetful cells that have lost the epigenetic memory of a healthy genome. 
Aging seems to be predisposed to this memory loss. One of the major challenges of the future 
regarding the treatment of aging and cancer, will be the identification of the framework of epigenetic 
changes that can restore this memory. 
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